DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
S••••••• R• A••••••••• L••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Principal held
at least $90.6M
sum of BDC pieces, a lower bound
Fair value
$89.5M
100c on cost, debt pieces
Unfunded
$14.6M
commitments not yet drawn
BDC lenders
3
3 on the latest quarter
Facilities
2
1 equity pieces beside them
Next maturity
Mar 1, 2033
no dated debt inside 24 months
On the tape since
Mar 31, 2026
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $90.5M | 100c | SOFR+475 bp | Mar 7, 2033 | 3 |
| first lien revolver first lien | at least $38,000 | n/a | SOFR+475 bp | Mar 7, 2033 | 3 |
Equity pieces beside the debt: other (n/a fair value, 1 BDC)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| B••• O•• C•••••• C••• | term loan first lien F•••• lien senior secured loan | N••••••••• | $25.8M | $25.5M 100c | S+475 bp |
| B••• O•• C•••••• C••• | revolver first lien F•••• lien senior secured revolving loan | n/a | $0 | |
| B••• O•• C••••• I••••• C•••• | revolver first lien F•••• lien senior secured revolving loan | N•••••••••/non-affiliated | n/a | n/a | |
| B••• O•• C••••• I••••• C•••• | term loan first lien F•••• lien senior secured loan | N••••••••• I••••• | $62.6M | $61.8M 100c | S+475 bp |
| M••••• A••••• I••••••••• P•••••• L•••••• | unstated lien unstated | n/a | n/a | |
| M••••• A••••• I••••••••• P•••••• L•••••• | revolver first lien F•••• L••• S•••••• D••• – R••••••• S+475, 0.50% F•••• M••••••• D••• 03/07/33 | $38,000 | $38,000 109c | SOFR+475 bp |
| M••••• A••••• I••••••••• P•••••• L•••••• | term loan first lien F•••• L••• S•••••• D••• - T••• L••• S+475, 0.50% F•••• M••••••• D••• 03/07/33 | $2.1M | $2.1M 101c | SOFR+475 bp |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3 | $90.6M | $89.5M | 100c | 0 |
| Mar 31, 2026 | 3 | $92.2M | $91.1M | 100c | 0 |
What changed
- New borrower on a BDC scheduleMar 31, 2026
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- SENDERRA RXderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 3 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it